- Bellus’ lead drug candidate, BLU-5937, has the potential to capture significant market share if the drug attains commercialization.
- Bellus has adequate cash on its books, lasting until at least the duration of 2022. The company has no long-term debt.
- Bellus claims 100% ownership of the intellectual property rights for both BLU-5937 and related P2X3 antagonists.
- Assuming a base case revenue of $320 million in the year 2028 and a P/S ratio of 6.0x, the company’s intrinsic value comes out to be $774 million or $9.80 per share, indicating an upside close to 3x.
For further details see:
Bellus Health - Betting Big On Chronic Cough Treatment